UK Markets open in 4 hrs 6 mins

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
24.67-1.24 (-4.79%)
At close: 04:00PM EST
24.67 0.00 (0.00%)
After hours: 04:00PM EST

Merus N.V.

Yalelaan 62
Utrecht 3584 CM
31 30 253 8800

Full-time employees93

Key executives

NameTitlePayExercisedYear born
Dr. Sven Ante LundbergCEO, Pres, Principal Financial Officer & Exec. Director986.82kN/A1963
Mr. Peter B. Silverman J.D.Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal614.88kN/A1978
Mr. Hui LiuChief Bus. Officer, Exec. VP & Head of Merus U.S.611.31kN/A1967
Dr. Hennie HoogenboomCo-Founder and Scientific AdvisorN/AN/AN/A
Mr. Cornelis Adriaan de Kruif Ph.D.CTO & Sr. VPN/AN/A1964
Dr. Cecile A.W. Geuijen Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Jillian ConnellVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Alexander Berthold Hendrik Bakker Ph.D.Chief Devel. Officer & Sr. VPN/AN/A1967
Dr. Andrew Joe M.D.Chief Medical OfficerN/AN/A1966
Ms. Anne Van der Touw NoordzijCompany Sec.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Corporate governance

Merus N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.